OraSure Technologies (OSUR) — This small-cap company develops, manufactures and markets oral fluid diagnostic products and specimen collection devices using its proprietary oral fluid technologies.
Jeffrey Saut of Raymond James mentioned the stock in connection with a recent Wall Street Journal article that noted millions of boomers may get a request to get tested for hepatitis C. Saut said that OSUR has one of the best tests for hepatitis C on the market. And with a potential cure for the disease possibly hitting the market soon, this company could be in a unique position to benefit from the demand for testing.
OSUR formed a bullish saucer, broke through its 200-day moving average and flashed a golden cross at $5.20. The stochastic indicator flashed a buy signal Wednesday, and the stock appears to be under accumulation and in a bull channel. Buy OSUR at the market as a long-term hold.